Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland. Show more
4800 Montgomery Lane, Bethesda, MD, 20814, United States
Market Cap
401.7M
52 Wk Range
$0.19 - $0.37
Previous Close
$0.25
Open
$0.26
Volume
1,204,584
Day Range
$0.25 - $0.26
Enterprise Value
469.9M
Cash
3.04M
Avg Qtr Burn
-14.76M
Insider Ownership
4.26%
Institutional Own.
0.06%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
DCVax-L (personalized immune therapy) Details Glioblastoma | NDA Acceptance for review |